Nebulised interferon-β1a (SNG001) in hospitalised COVID-19: SPRINTER phase III study

Although the primary objective of the study was not met, SNG001 had a favourable safety profile, and the key secondary end-points analysis suggested that SNG001 may have prevented progression to severe disease.